Want to see JP:4882 full AI Analyst Report?
Top Page
Perseus Proteomics, Inc.
(4882)
Select Model
Select Model
Rating:48Neutral
Price Target:
¥173.00
▼(-21.36% Downside)
Action:Reiterated
Date:09/09/26
The score is held back primarily by weak financial performance—large ongoing losses, sustained cash burn, and declining equity—despite solid revenue growth and a debt-free balance sheet. Technicals are moderately supportive in the short term (positive MACD and price above short-term averages), but the longer-term trend remains weak. Valuation is constrained by negative earnings and the absence of dividend support.
Positive Factors
Strong Revenue Growth
Revenue has nearly doubled across the reported period, demonstrating sustained commercial expansion and growing customer or product demand. Continued top-line growth can improve operating leverage over time and provides a larger base from which the company may eventually build durable profitability.
Negative Factors
Persistent Operating Losses
Large recurring EBIT and net losses indicate that revenue growth has not yet translated into a viable earnings model. Until operating expenses become better aligned with sales, the company remains exposed to continued value destruction and has limited ability to fund expansion through internally generated profits.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
Revenue has nearly doubled across the reported period, demonstrating sustained commercial expansion and growing customer or product demand. Continued top-line growth can improve operating leverage over time and provides a larger base from which the company may eventually build durable profitability.
Read all positive factors
Perseus Proteomics, Inc. (4882) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥3.23B
Dividend YieldN/A
Average Volume (3M)725.94K
Price to Earnings (P/E)―
Beta (1Y)1.43
Revenue Growth19.70%
EPS Growth17.73%
CountryJP
Employees35
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)-48.09
Shares Outstanding18,429,500
10 Day Avg. Volume465,320
30 Day Avg. Volume725,943
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)2.69
Price to Sales (P/S)24.20
P/FCF Ratio-4.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-62.5
Revenue Forecast (FY)¥120.00M
Perseus Proteomics, Inc. Business Overview & Revenue Model
Company Description
Based in Tokyo, Japan, Perseus Proteomics Inc. operates as a biotechnology venture specializing in the development of antibody-based therapeutics for various ailments, including cancer. Its core operations encompass pioneering antibody discovery, ...
How the Company Makes Money
null...
Perseus Proteomics, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 147.22M | 135.51M | 120.38M | 100.40M | 94.20M | 71.93M |
| Gross Profit | 126.49M | 116.16M | 104.05M | 87.69M | 86.53M | 67.75M |
| EBITDA | -744.74M | -715.80M | -899.49M | -1.10B | -779.36M | -594.14M |
| Net Income | -744.64M | -718.11M | -904.80M | -1.10B | -787.00M | -599.02M |
Balance Sheet | ||||||
| Total Assets | 1.67B | 1.62B | 1.82B | 1.69B | 2.57B | 3.30B |
| Cash, Cash Equivalents and Short-Term Investments | 1.59B | 1.52B | 1.67B | 1.54B | 2.44B | 3.21B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 442.44M | 405.77M | 386.43M | 295.46M | 170.10M | 148.38M |
| Stockholders Equity | 1.22B | 1.22B | 1.43B | 1.40B | 2.40B | 3.15B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -662.83M | -794.64M | -976.90M | -734.82M | -510.71M |
| Operating Cash Flow | 0.00 | -653.33M | -719.49M | -833.90M | -564.27M | -476.84M |
| Investing Cash Flow | 0.00 | -10.06M | -75.16M | -150.34M | -212.99M | -33.87M |
| Financing Cash Flow | 0.00 | 497.33M | 923.38M | 63.94M | -20.00K | 2.65B |
Perseus Proteomics, Inc. Technical Analysis
Positive
220.00
Price Trends
151.70
Positive
158.94
Positive
201.10
Negative
Market Momentum
8.13
Negative
59.68
Neutral
57.65
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4882, the sentiment is Positive. The current price of 220 is above the 20-day moving average (MA) of 159.60, above the 50-day MA of 151.70, and above the 200-day MA of 201.10, indicating a neutral trend. The MACD of 8.13 indicates Negative momentum. The RSI at 59.68 is Neutral, neither overbought nor oversold. The STOCH value of 57.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4882.
Perseus Proteomics, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ¥3.63B | 16.82 | ― | 2.96% | -2.27% | -17.23% | |
69 Neutral | ¥7.26B | 19.38 | ― | 4.02% | 9.39% | 44.42% | |
57 Neutral | ¥5.84B | 14.64 | ― | 0.95% | 11.17% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | ¥4.32B | 130.87 | ― | 1.25% | 2.37% | ― | |
48 Neutral | ¥3.23B | -3.56 | ― | ― | 19.70% | 17.73% | |
44 Neutral | ¥14.44B | -30.72 | ― | ― | -18.71% | -246.54% |
* General Sector Average
JP:4882
Perseus Proteomics, Inc.
171.00
-149.00
-46.56%
JP:2342
Trans Genic Inc.
251.00
34.00
15.67%
JP:3386
Cosmo Bio Co., Ltd.
1,243.00
73.57
6.29%
JP:4978
ReproCELL Inc.
141.00
-60.00
-29.85%
JP:6090
Human Metabolome Technologies, Inc.
609.00
-119.67
-16.42%
JP:7707
Precision System Science Co.,Ltd
211.00
-1.00
-0.47%
Perseus Proteomics, Inc. Corporate Events
Perseus Proteomics Flags FX Gains, Financing Costs and Asset Impairment in Q2 Results
Aug 13, 2026
Perseus Proteomics Inc. reported several non-operating and extraordinary items in its non-consolidated financial results for the quarter ended June 30, 2026. The biotech firm’s disclosure highlights movements in foreign exchange, financing-r...
Perseus Proteomics Narrows Loss as Sales Rise but Withholds Full-Year Outlook
Aug 13, 2026
Perseus Proteomics Inc. reported non-consolidated results for the quarter ended June 30, 2026, showing net sales of ¥35 million, up 49.9% year on year but still posting an operating loss of ¥204 million and a net loss of ¥202 millio...
Perseus Proteomics Reports Durable Phase I Follow-Up Results for PPMX-T003 in Polycythemia Vera
Jul 1, 2026
Perseus Proteomics reported results from a follow-up clinical study involving patients who participated in the Phase I trial of its investigational drug PPMX-T003 for polycythemia vera. Among six patients treated, four required no therapeutic phle...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.